* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
As a leading provider of drug discovery and research services, BOC Sciences is committed to providing a one-stop services for the development of targeted protein degraders. ATTEC, a novel small molecule degrader that harnesses an important intracellular protein degradation pathway, macroautophagy, to control levels of disease related proteins. With a comprehensive and advanced platform, we provide ATTEC design, synthesis, optimization and assay services to our global customers to achieve new drug discovery goals.
Many diseases are caused by the abnormal accumulation of certain misfolded and cytotoxic proteins, and reducing the levels of these proteins offers promising therapeutic strategies for these diseases. Although PROTACs provide promising therapeutic strategies for degrading pathogenic proteins using the ubiquitin-proteasome degradation systems, some disease-causing protein aggregates or non-protein disease-causing biomolecules may not be effectively degraded by the proteasome. The lysosomal degradation system as another important intracellular degradation pathway has expanded the research horizon in the field of targeted protein degradation.
The autophagy-lysosome pathway is the major degradation pathway that occurs in all eukaryotic cells. Autophagy is a cellular process in which the cytoplasmic contents are degraded within lysosomes/vesicles and the resulting macromolecular components are recycled. Macroautophagy is an autophagic process in which substrates are isolated in cytosolic double-membrane vesicles called autophagosomes.
ATTEC (autophagosome-tethering compound) is able to interact with the phagophore protein LC3 (It can be lipidated to form autophagosome) and protein substrates to bind the target protein to the phagocyte for subsequent autophagic degradation. There is evidence that autophagic protein substrates are engulfed in double-membrane phagocytes associated with lipidated LC3 proteins.
Fig 1. Mechanism of action of ATTEC (Li, 2020)
ATTEC can be applied to many disease-causing proteins or other biomolecules to treat diseases.
Fig 2. Mechanism of action of ATTEC-mediated lipid degradation (Fu, 2021)
BOC Sciences provides lysosomal-based ATTEC development services. Our one-stop services include but not limited to:
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.